Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.42 |
| ▸ | WDR5 | P61964 | 15/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21884437 | 0.91 | WDR5 (0.35) | NISCHWDR5LRRK2ADRA1DSLC6A3 | |
| SCHEMBL21884376 | 0.91 | PDE4B (0.37) | WDR5LRRK2ADRA1DSLC6A3 | |
| SCHEMBL21884432 | 0.90 | TMPRSS4 (0.40) | WDR5LRRK2HTT | |
| SCHEMBL24066318 | 0.89 | WDR5 (0.36) | WDR5HTTADRA1D | |
| SCHEMBL21884629 | 0.88 | WDR5 (0.40) | WDR5 | |
| SCHEMBL21884363 | 0.87 | NISCH (0.41) | NISCHWDR5ADRA1DSLC6A3 | |
| SCHEMBL21884371 | 0.85 | ABL1 (0.36) | NISCHWDR5ADRA1DSLC6A3 | |
| SCHEMBL21884365 | 0.83 | NISCH (0.38) | NISCHWDR5ADRA1DSLC6A3 | |
| SCHEMBL21884370 | 0.83 | LRRK2 (0.38) | WDR5LRRK2ADRA1DSLC6A3 | |
| SCHEMBL21884640 | 0.83 | NISCH (0.35) | NISCHWDR5HTTADRA1DSLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS INC. | 2021-12-02 | — | — | US | disclosed |
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | JNANA THERAPEUTICS INC. | 2021-09-30 | — | — | US | disclosed |
| WO-2020061473-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | SLC19A1, SLC1A5, SLC1A2 | NISCH 1713/4885WDR5 3394/4885LRRK2 3750/4885 |
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | SNRPE, G3BP1, G3BP2 | NISCH 4403/4885WDR5 1567/4885LRRK2 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.